HAMPTON, Va., June 3, 2011/PRNewswire-USNewswire/ -- Patient
Advocate Foundation (PAF) is pleased to announce that it has
received a new contribution enabling it to begin offering support
to patients suffering with nonsquamous non-small cell lung cancer
(NSCLC) through its Co-Pay Relief Program (CPR) on June 6, 2011 at
11:00 AM EDT. PAF is a national non-profit organization that seeks
to safeguard patients through effective mediation assuring access
to care, maintenance of employment and preservation of their
financial stability relative to their diagnosis of life threatening
or debilitating diseases.

PAF's Co-Pay Relief Program provides direct financial support
for pharmaceutical co-payments to insured patients, including
Medicare Part D beneficiaries, who financially and medically
qualify. Since the program's inception in April 2004, CPR
distributed more than $120 million in assistance to more than
46,000 patients who were unable to afford their pharmaceutical
co-payments.

"A debilitating or life-threatening diagnosis can be the most
overwhelming experience a person may ever face in his or her
lifetime. Coupled with high-cost pharmaceutical co-pay expenses,
the journey can become significantly more challenging to manage,"
said Nancy Davenport-Ennis, Founder and CEO of PAF. "Patient
Advocate Foundation created the Co-Pay Relief Program in 2004 after
receiving an increased number of patients seeking co-pay assistance
for pharmaceutical drugs, so we are particularly pleased to be able
to offer assistance to more patients every year."

Globally, lung cancer is the most common form of cancer and the
biggest killer, causing 1.3 million cancer deaths annually.
About 85 – 90 percent of all lung cancers are NSCLC.
The liver, bones and brain are potential targets if the cancerous
cells enter the bloodstream. NSCLC comprises a group of histologies
or tumor types differentiated by cellular structure. Nonsquamous
histology includes ad

HAMPTON, Va., June 3, 2011/PRNewswire-USNewswire/ -- Patient Advocate Foundation (PAF) is pleased to announce that it has received a new contribution enabling it to begin offering support to patients suffering with nonsquamous non-small cell lung cancer (NSCLC) through its Co-Pay Relief...